Antoinette Tan

Trials

Studies that name Antoinette Tan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:39 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06027268 · Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

  Wake Forest University Health Sciences · active not recruiting · Metastatic Triple-Negative Breast Cancer · principal investigator
• Ph1
  NCT04762901 · LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

  Wake Forest University Health Sciences · withdrawn · Breast Cancer · principal investigator
• Ph2
  NCT03018080 · Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

  Wake Forest University Health Sciences · completed · Breast - Female, Male Breast Cancer · principal investigator
• Ph2
  NCT02942355 · Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

  Wake Forest University Health Sciences · active not recruiting · Female Breast Carcinoma, Breast Cancer · principal investigator
• Ph1/Ph2
  NCT00634634 · Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

  Rutgers, The State University of New Jersey · completed · Metastatic Breast Cancer · principal investigator
• Ph1
  NCT00450879 · Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

  National Cancer Institute (NCI) · terminated · Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)
  U01CA132194 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ROBERT S. DIPAOLA · fiscal years 2008 to 2013
  Named on NCT00450879
• Cancer Center Administration
  P30CA072720 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI John Pounardjian · fiscal years 1997 to 2026
  Named on NCT00450879